Nanoform Partners with Revio Therapeutics
Nanoform Finland Plc, a medicine performance-enhancing company, announced a partnership with Revio Therapeutics, a specialty pharma company, to co-develop and commercialize GLIORA.
GLIORA is a nano-formulated combination of olaparib (Lynparza) and temozolomide (Temodar) as a locally-administered, long-acting, thermo-responsive hydrogel, for the treatment of high-grade glioma.
Nanoform Finland Plc ("Nanoform") partners with Revio Therapeutics ("Revio") to develop GLIORA for high-grade glioma treatment.
- Partnership between Nanoform Finland Plc and Revio Therapeutics
- Co-development and commercialization of GLIORA
- Treatment for high-grade glioma, a fast-growing and aggressive type of brain tumor
Author's summary: Nanoform partners with Revio Therapeutics to develop GLIORA for glioma treatment.
More News
- Community pharmacies and BioPharma: Advancing whole-patient care together
- Kymera Therapeutics, Inc.: Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual Meeting
- Retinal Textural Changes on OCT May Show Early Diabetic Change
- Here’s why Utah’s Olympic organizers are in NYC this week
- Deadline is Dec. 31 to apply for Renew NC grants - Hendersonville Lightning
- Canada’s Lululemon Partners With National Football League
- Tapering Methotrexate Is Feasible in Stable RA With Careful Monitoring
- Early TNF Inhibitor Use Improves Outcomes in Nonsystemic JIA
- The new age of pediatric medication awareness - Express Healthcare
- Renters’ Rights Bill does not protect tenants only council budgets warns expert